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AbstrACt
Objective Estimate the incidence of placenta accreta and 
describe risk factors, clinical practice and perinatal outcomes.
Design Case–control study.
setting Sites in Australia and New Zealand with at least 
50 births per year.
Participants Cases were women giving birth (≥20 weeks 
or fetus ≥400 g) who were diagnosed with placenta 
accreta by antenatal imaging, at operation or by pathology 
specimens between 2010 and 2012. Controls were two 
births immediately prior to a case. A total of 295 cases 
were included and 570 controls.
Methods Data were collected using the Australasian 
Maternity Outcomes Surveillance System.
Primary and secondary outcome measures Incidence, 
risk factors (eg, prior caesarean section (CS), maternal 
age) and clinical outcomes of placenta accreta (eg CS, 
hysterectomy and death).
results The incidence of placenta accreta was 44.2/100 000 
women giving birth (95% CI 39.4 to 49.5); however, this may 
overestimated due to the case definition used. In primiparous 
women, an increased odds of placenta accreta was observed 
in older women (adjusted OR (AOR) women≥40 vs <30: 19.1, 
95% CI 4.6 to 80.3) and current multiple birth (AOR: 6.1, 
95% CI 1.1 to 34.1). In multiparous women, independent risk 
factors were prior CS (AOR ≥2 prior sections vs 0: 13.8, 95% CI 
7.4 to 26.1) and current placenta praevia (AOR: 36.3, 95% CI 
14.0 to 93.7). There were two maternal deaths (case fatality 
rate 0.7%). Women with placenta accreta were more likely to 
have a caesarean section (AOR: 4.6, 95% CI 2.7 to 7.6) to be 
admitted to the intensive care unit (ICU)/high dependency unit 
(AOR: 46.1, 95% CI 22.3 to 95.4) and to have a hysterectomy 
(AOR: 209.0, 95% CI 19.9 to 875.0). Babies born to women 
with placenta accreta were more likely to be preterm, be 
admitted to neonatal ICU and require resuscitation.
IntrODuCtIOn
Placenta accreta is an uncommon condition 
occurring during pregnancy which is char-
acterised by abnormal placentation. The 
severity of abnormal placentation can be 
classified into three grades based on histopa-
thology: the least severe and most common 
presentation is placenta accreta, in which the 
placental villi penetrate only to the surface 
of the myometrium. Placenta increta is char-
acterised by invasion of placental villi into 
the myometrium. The most severe form is 
placenta percreta, characterised by inva-
sion of villi beyond the myometrium to the 
uterine serosa and in some cases involving 
adjacent organs such as the bladder.1 The 
term ‘placenta accreta’ refers to all three 
conditions in this paper. Placenta accreta is 
associated with major pregnancy complica-
tions such as massive blood loss and hyster-
ectomy and is potentially life threatening. 
Once the diagnosis of placenta accreta is 
established, the decision about mode of birth 
requires multidisciplinary team planning and 
often involves complex surgery or radiolog-
ical interventions to reduce maternal and 
neonatal morbidity.2 3
The incidence of placenta accreta is 
believed to be increasing globally.2 3 This is 
likely attributable to an increase in caesarean 
sections and trends towards older women 
giving birth, both of which are independent 
strengths and limitations of this study
 ► This is the first national and binational case–control 
study of placenta accreta in Australia and New 
Zealand.
 ► This case–control study used active surveillance of 
cases by dedicated researchers, limiting recall bias 
and errors common in administrative datasets.
 ► This study may have included cases which were 
diagnosed antenatally but which were not confirmed 
clinically at operation or on pathology and therefore 
not true cases of placenta accreta.
 ► Denominator data for the number of births in 
Australian hospitals is an estimate because of the 
varying start time for hospitals in the study.
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risk factors for placenta accreta.4 5 There are a growing 
number of caesarean sections in Australia and New 
Zealand6; however, the epidemiology and clinical prac-
tices for managing placenta accreta in these countries 
has not been previously reported. The prevalence of 
risk factors for this condition may be different in the 
Australian and New Zealand population, such as the prev-
alence of previous caesarian births. A case–control study 
with active surveillance was undertaken with the aim of 
estimating the incidence of placenta accreta in Australia 
and New Zealand and describing risk factors, clinical 
practices and outcomes for women affected by this condi-
tion and their babies.
MAterIAls AnD MethODs
A binational population-based case–control study was 
undertaken using the research platform of the Austral-
asian Maternity Outcomes Surveillance System (AMOSS). 
AMOSS was established across maternity units in Australia 
and New Zealand in 2009 to study rare and serious disor-
ders of pregnancy.7 8 There were six studies conducted 
contemporaneously including studies on: amniotic fluid 
embolism, antenatal pulmonary embolism, eclampsia, 
super obesity and peripartum hysterectomy, which used 
a similar study design and data collection methodology. 
Data were collected from participating sites, which were 
public and private maternity units with more than 50 
births per year in Australia and New Zealand, incorpo-
rating all service levels. Australian sites (n=269) progres-
sively joined AMOSS on completion of relevant ethics 
and governance approvals. In New Zealand, all 24 mater-
nity units participated (100% of hospital births).8
Women were identified by AMOSS-participating sites 
from January 2010 to December 2011 (Australia) and 
to December 2012 (New Zealand). All AMOSS hospi-
tal-based data collectors received study information on 
the surveillance period, recruitment, case definition and 
inclusion and exclusion criteria. Central support was 
available for local data collectors, including confirmation 
that individual cases satisfied the inclusion criteria. Nomi-
nated clinicians and midwives were contacted each month 
using an active surveillance system, querying whether a 
case had occurred that month. Data collectors identified 
cases through multiple sources: review of routine data 
collection within the hospital, audit committees, clinician 
notification and request to clinicians of potential cases. 
The average monthly response rate was 91%.
Cases were defined as: women giving birth who were 
diagnosed with placenta accreta by either antenatal 
imaging, at operation or by pathology specimens. The 
type of diagnosis was recoded according to the earliest 
diagnosis. For example, a case diagnosed both by ante-
natal imaging and by pathology specimen was coded as 
diagnosed by antenatal imaging. Giving birth was defined 
as the birth of one or more live or stillborn infants of at 
least 400 g birth weight and/or at least 20 weeks’ gesta-
tion.9 10 The two women giving birth immediately prior 
to the case in the same hospital were selected as controls. 
Perinatal deaths included fetal deaths of at least 400 g 
birth weight or 20 weeks’ gestation and neonatal deaths 
occurring within 28 days after birth.
Data were collected using secure, web-based forms 
which captured general demographic and pregnancy 
data and case-specific information about prior obstetric 
history, current pregnancy and placenta accreta diagnosis 
and clinical practice, such as use of hysterectomy. For 
controls, the outcome of hysterectomy was obtained from 
a free-text field on maternal morbidity and by probabi-
listic matching against the AMOSS hysterectomy cohort.
Data collectors at participating hospitals were contacted 
regarding missing data or where data were not consistent 
with expected values. Logic checks were run on the data 
to identify any impossible or improbable scenarios. Free-
text responses to questions regarding medical or obstetric 
morbidity were classified according to International Clas-
sification of Disease 10th Revision—Australian Modifica-
tion. All data were collected in a non-identifiable manner.
Ethics approval for AMOSS was granted by the New 
South Wales Population and Health Services Research 
Ethics Committee and multiple Human Research Ethics 
Committees across Australia and the multiregional ethics 
approval (MEC/09/73/EXP) in New Zealand.11
After adjusting for the phased implementation of 
AMOSS, there were an estimated 478 820 women giving 
birth (486 003 babies born) in Australia and 189 116 
(190 408 babies born) in New Zealand across the partic-
ipating maternity sites during the study period. In New 
Zealand, these denominators were calculated from the 
Ministry of Health data12–14 and in Australia by using the 
number of days’ participation in the study multiplied by 
number of births per day for that hospital, which gave 
approximate coverage ranging from 75% in 2010 to 82% 
in 2011 of all women giving birth in Australia, respectively. 
Incidence rates were calculated with 95% CIs. Fisher’s 
exact test, χ2 test, independent samples t-test and Mann–
Whitney U-test were used to investigate differences in 
demographics and obstetric characteristics, maternal and 
perinatal outcomes between cases and the controls. Multi-
variate logistic regression was used to examine the risk 
factors for placenta accreta by parity and to compare the 
maternal and perinatal outcomes of cases and controls. 
OR, odds ratio (AOR) and 95% CI were calculated. 
Adjustment was made for maternal age, body mass index 
(BMI), smoking status during pregnancy, parity, number 
of previous caesarean births, placenta praevia during 
pregnancy, multiple pregnancies and assisted reproduc-
tive technologies. Data were analysed using the Statistical 
Package for the Social Sciences software V. 22.0 (IBM).
results
Of the 308 cases notified to AMOSS, 295 were eligible after 
excluding 13 cases; 7 outside the study period, 3 dupli-
cate notifications and 3 not satisfying the birth definition. 
Of the 295 cases, 227 women were from Australia and 68 
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from New Zealand. Data were available for 570 controls, 
as the data for 20 controls was missing.
The incidence of placenta accreta for the study period 
was 44.2/100 000 women giving birth (95% CI 39.4 to 
49.5). The incidences in Australia and New Zealand were 
47.4/100 000 (95% CI 41.6 to 54.0) and 36.0/100 000 
(95% CI 28.4 to 45.6), respectively. There were 12 peri-
natal deaths among the cases (perinatal death rate 38.7 
per 1000 births) and 10 among the controls (perinatal 
death rate 17.2 per 1000 births). There were two maternal 
deaths among the cases, resulting in a case fatality rate 
of 0.7%. The causes of maternal death were cerebrovas-
cular accident secondary to pulmonary embolism and 
catastrophic postpartum haemorrhage due to placenta 
accreta. There were no maternal deaths among controls.
Almost half of the cases were first diagnosed by antenatal 
imaging (143, 48.5%), 132 (44.7%) were first diagnosed 
clinically at operation, and 16 (5.4%) were not diagnosed 
until histological confirmation following delivery; in four 
cases, the time of diagnosis was not reported. In total, 184 
(62%) cases were reported as being diagnosed at operation 
or by histology, and 107 cases reported as being diagnosed 
by antenatal imaging only (36%). There were 213 (72.2%) 
cases with placenta accreta, 37 (12.5%) with placenta increta 
and 45 (15.3%) with placenta percreta, diagnosed by at least 
one of antenatal imaging, operation or histology.
The median age of women with placenta accreta was 
35 years (range 21–55) and the median BMI was 28 kg/
m2 (range 16.3–57.8) (table 1). Over 80% of placenta 
accreta cases had a previous birth and 68% had a previous 
caesarean section. Eight per cent of pregnancies among 
the  cases were conceived following assisted reproductive 
technologies and 5% of the cases had current multiple 
pregnancies. Forty-four per cent of cases also had placenta 
praevia diagnosed prior to the birth (table 1).
Women with placenta accreta were more likely to be 
older, have a higher BMI, a previous birth, previous 
caesarean section, placenta praevia diagnosed prior to 
delivery, current multiple pregnancy and to have conceived 
following assisted reproductive technologies (table 1).
Multivariate analysis was conducted separately for prim-
iparous and multiparous women, as previous caesarean 
section is only applicable to women with a previous birth. 
In primiparous women, maternal age remained an inde-
pendent risk factor for placenta accreta; mothers 40 or 
over had more than a 19-fold higher odds of placenta 
accreta compared with young mothers aged less than 30 
(table 2). The presence of a current multiple pregnancy 
was also a risk factor for placenta accreta in primiparous 
women (AOR: 6.1, 95% CI 1.1 to 34.1). In multiparous 
women, the independent risk factors were prior caesarean 
section (AOR ≥2 prior sections vs 0: 13.8, 95% CI 7.4 to 
26.1) and current placenta praevia (AOR: 36.3, 95% CI 
14.0 to 93.7). Current placenta praevia was present in 
50.2% of multiparous cases, compared with 10.8% of 
primiparous cases.
As the management of cases is expected to differ 
according to the knowledge of a placenta accreta, the cases 
Table 1 Demographics and obstetric characteristics
Case Control
p ValueN (%) N (%)
Total 295 (100.0) 570 (100.0)
Country
  Australia  227 (76.9) 436 (76.5) 0.88
  New Zealand 68 (23.1) 134 (23.5)
Maternal age
  <25 7 (2.4) 93 (16.3) <0.001
  25–29 44 (14.9) 147 (25.8)
  30–34 94 (31.9)  177 (31.1)
  35–39 112 (38.0) 121 (21.2)
  ≥40 38 (12.9) 32 (5.6)
Indigenous status (Australian only)
  Yes 11 (4.8) 13 (3.0) 0.21
  No 202 (89.0) 403 (92.4)
  Not stated 14 (6.2) 20 (4.6)
Ethnicity (New Zealand only)
  Maori 13 (19.1) 18 (13.4) 0.34
  New Zealand 
European
34 (50.0)  63 (47.0)
  Pacific peoples 5 (7.4) 17 (12.7)
  Other 12 (17.6) 34 (25.4)
  Not stated 4 (5.9) 2 (1.5)
Body mass index (kg/m2)
  <25 115 (39.0)  272 (47.7) <0.05
  25–29.9 66 (22.4) 128 (22.5)
  ≥30 78 (26.4) 112 (19.6)
  Not stated 36 (12.2) 58 (10.2)
Smoking during pregnancy
  Yes 56 (19.0) 97 (17.0) 0.45
  No 215 (72.9) 429 (75.3)
  Not stated 24 (8.1) 44 (7.7)
Parity
  0 46 (15.6) 240 (42.1) <0.001
  1–2 159 (53.9) 274 (48.1)
  ≥3 90 (30.5) 56 (9.8)
Number of previous caesarean deliveries
  No prior caesarean 
delivery
43 (14.6) 225 (39.5) <0.001
  1 89 (30.2) 80 (14.0)
  2 62 (21.0) 19 (3.3)
  ≥3 50 (16.9) 3 (0.5)
  Not applicable (no 
prior births)
46 (15.6) 240 (42.1)
  Not stated 5 (1.7) 3 (0.5)
Last pregnancy delivery by caesarean delivery
Continued
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were categorised by whether or not the placenta accreta 
was suspected prior to birth (table 3). Of the cases, 169 
(57.3%) had a placenta accreta suspected prior to birth. 
On average, women with a suspected placenta accreta 
had a more severe condition; 57 (33%) of suspected cases 
had a placenta increta or percreta compared with 24 
(19.5%) of non-suspected cases. Women with suspected 
placenta accreta were also more likely to have had a prior 
caesarean section (93%) than women with unsuspected 
placenta accreta (72%).
Cases were less likely to labour than controls (20% vs 
79%); the majority of cases who laboured had an unsus-
pected placenta accreta (table 3). The one case with 
placenta accreta suspected prior to delivery that laboured 
had a termination of pregnancy at 20 weeks. Additionally, 
cases were more likely to: give birth at an earlier gesta-
tion, to have a caesarean section, to be admitted to a high 
dependency unit (HDU) and to have a hysterectomy. 
Cases with a suspected placenta accreta were more likely 
to undergo hysterectomy than cases in which placenta 
accreta was not suspected prior to delivery (142/169; 84% 
vs 53/123; 43%), and both were more likely to undergo 
hysterectomy than controls (2/570; 0.4% underwent 
hysterectomy). In the two controls that required a hyster-
ectomy, the underlying cause of haemorrhage was uterine 
atony. Of cases undergoing hysterectomy, 15 (7.7%) had 
no previous birth.
After adjusting for confounding factors, cases remained 
more likely to have a caesarean delivery (AOR: 4.6, 95% CI 
2.7 to 7.6) to be admitted to the intensive care unit (ICU)/
HDU (AOR: 46.1, 95% CI 22.3 to 95.4), and to have a 
hysterectomy (AOR: 209.0, 95% CI 19.9 to 875.0). These 
Case Control
p ValueN (%) N (%)
  Yes 188 (63.7) 91 (16.0) <0.001
  No 55 (18.6) 234 (41.1)
  Not applicable (no 
prior births)
46 (15.6) 240 (42.1)
  Not stated 6 (2.0) 5 (0.9)
Placenta praevia during pregnancy
  Yes 130 (44.1) 8 (1.4) <0.001
  No 165 (55.9) 562 (98.6)
Multiple pregnancy
  Yes 15 (5.1) 13 (2.3) <0.05
  No 280 (94.9) 555 (97.4)
  Not stated 0 (0.0) 2 (0.4)
Assisted conception
  Yes 24 (8.1) 15 (2.6) <0.001
  No 259 (87.8) 521 (91.4)
  Not stated 12 (4.1) 34 (6.0)
Table 1 Continued 
Table 2 Risk factor analysis including cases and controls
Primiparous women Multiparous women
OR (95% CI) AOR (95% CI)* OR (95% CI) AOR (95% CI)†
Maternal age
  <30 Ref Ref Ref Ref
  30–34 8.0 (2.6 to 24.9) 6.3 (2.0 to 20.0) 1.7 (1. to 2.7) 1.7 (0.9  to 3.2)
  35–39 11.0 (3.5 to 34.9) 7.0 (2.1 to 23.6) 3.1 (2.0 to 4.8) 2.7 (1.4 to 5.2)
  ≥40 30.7 (8.2 to 115.9) 19.1 (4.6 to 80.3) 3.1 (1.6 to 6.0) 2.0 (0.8 to 5.0)
Body mass index (kg/m2)
  <25 Ref Ref Ref Ref
  25–29.9 1.2 (0.6 to 2.6) 1.4 (0.6 to 3.2) 1.1 (0.7 to 1.8) 0.8 (0.4 to  1.4)
  ≥30 0.7 (0.3 to 2.0) 0.7 (0.2 to 2.2) 1.4 (0.9 to 2.1) 0.8 (0.5 to  1.4)
  Smoking during pregnancy 0.2 (0.1 to 1.0) 0.4 (0.1 to 1.8) 1.3 (0.9 to 2.0) 1.3 (0.7 to  2.4)
Number of previous caesarean births
  No prior caesarean delivery n.a n.a Ref Ref
  1 n.a n.a 5.8 (3.7 to 9.1) 3.7 (2.2  to 6.3)
  ≥2 n.a  n.a 24.8 (14.3 to 43.1) 13.8 (7.4 to 26.1)
  Placenta praevia during pregnancy 9.6 (2.2 to 41.9) 3.0 (0.6 to 15.2) 64.9 (25.9 to 162.5) 36.3 (14.0 to93.7)
  Multiple pregnancy 14.2 (3.5 to 57.2) 6.1 (1.1 to 34.1) 1.1 (0.4 to 2.7) 1.5 (0.5 to 4.9)
  Assisted conception 5.4 (2.2 to 13.1) 1.5 (0.5 to 5.1) 4.4 (1.4 to 13.7) 2.6 (0.6 to 11.2)
*Adjusted for maternal age, body mass index, smoking, placenta praevia during pregnancy, multiple pregnancy and assisted conception.
†Adjusted for maternal age, body mass index, smoking, number of previous caesarean deliveries, placenta praevia during pregnancy, multiple 
pregnancy and assisted conception
 AOR, adjusted OR; n.a., not applicable; Ref, reference value.
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analyses were adjusted for maternal age, BMI, smoking, 
number of previous caesarean sections, placenta praevia 
diagnosed prior to delivery, multiple pregnancy and use 
of assisted reproductive technologies.
Babies born to mothers with placenta accreta were more 
likely to be preterm (median gestational age at birth 36 vs 
39 weeks) and have lower birth weights, with 40% vs 9% of 
babies born weighing 2500 g or less (table 4). These babies 
were also more likely to have an Apgar score of 7 or less 
5 min after birth, require resuscitation and to be admitted 
to a neonatal intensive care unit (NICU). Among cases, 
there was a higher chance of being discharged to another 
health facility and of neonatal death.
In the multivariate analysis, the following baby’s 
outcomes remained significantly associated with placenta 
accreta: preterm birth (AOR: 5.0 95% CI 3.2 to 7.8), low 
birth weight (AOR: 5.0, 95% CI 2.9 to 8.4), admission to 
NICU (AOR: 4.4, 95% CI 2.8 to 6.9), Apgar 5 min<7 (AOR: 
Table 3 Labour, birth and maternal morbidity among cases with suspected and unsuspected placenta accreta prior to 
delivery and controls
Case
Control (n=570)
p Value*
PA suspected 
antenatally
(n=169)
PA not suspected 
antenatally
(n=123) Total† (n=295)
N (%) N (%) N (%) N (%)
Did the woman labour
  Yes 7 (4.1) 51 (41.5) 59 (20.0) 451 (79.1) <0.001
  No 162 (95.9) 72 (58.5) 236 (80.0) 117 (20.5)
  Not stated 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.4)
Induced labour
  Yes 1 (14.3) 16 (31.4) 17 (28.8) 116 (25.7) 0.55
  No 5 (71.4) 34 (66.7) 40 (67.8) 329 (72.9)
  Not stated 1 (14.3) 1 (2.0) 2 (3.4) 6 (1.3)
Gestation at birth, weeks, median 35.0 38.0 36.0 39.0 <0.001
Method of birth
  Unassisted vaginal birth 1 (0.6) 30 (24.4) 31 (10.5) 314 (55.1) <0.001
  Instrumental vaginal birth 0 (0.0) 5 (4.1) 5 (1.7) 71 (12.5)
  Planned caesarean birth 140 (82.8) 50 (40.7) 190 (64.4) 107 (18.8)
  Unplanned caesarean birth 28 (16.6) 38 (30.9) 69 (23.4) 77 (13.5)
  Not stated 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2)
Admission to ICU
  Yes 65 (38.5) 40 (32.5) 105 (35.6) 6 (1.1) <0.001
  No 104 (61.5) 81 (65.9) 188 (63.7) 564 (98.9)
  Not stated 0 (0.0) 2 (1.6) 2 (0.7) 0 (0.0)
Admission to HDU
  Yes 68 (40.2) 32 (26.0) 101 (34.2) 8 (1.4) <0.001
  No 100 (59.2) 89 (72.4) 191 (64.7) 562 (98.6)
  Not stated 1 (0.6) 2 (1.6) 3 (1.0) 0 (0.0)
Had hysterectomy
  Yes 142 (84.0) 53 (43.1) 196 (66.4) 2 (0.4) <0.001
  No 27 (16.0) 69 (56.1) 98 (33.2) 568 (99.6)
  Not stated 0 (0.0) 1 (0.8) 1 (0.3) 0 (0.0)
Maternal death
  Yes 1 (0.6) 1 (0.8) 2 (0.7) 0 (0.0) 0.12
  No 168 (99.4) 122 (99.2) 293 (99.3) 570 (100.0)
*Total number of cases versus control.
†Includes three cases where it was not known whether PA was suspected prior to birth.
ICU, intensive care unit; HDU, high dependency unit; PA, placenta accreta.
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Table 4 Perinatal outcomes among births born to women with suspected and unsuspected placenta accreta prior to delivery 
and controls
Case Control (n=582) p Value*
PA suspected 
antenatally (n=174)
PA not suspected 
antenatally (n=133) Total† (n=310)
N (%) N (%) N (%) N (%)
Fetal deaths 5 (2.9) 4 (3.0) 9 (2.9) 5 (0.9) <0.05
Perinatal deaths 7 (4.0) 5 (3.8) 12 (3.9) 10 (1.7) <0.05
Sex
  Male 87 (50.0) 55 (41.4) 142 (45.8) 281 (48.3) 0.53
  Female 84 (48.3) 78 (58.6) 165 (53.2) 299 (51.4)
  Not stated 3 (1.7) 0 (0.0) 3 (1.0) 2 (0.3)
Gestational age, weeks, 
median
35.0 38.0 36.0 39.0 <0.001
Preterm birth (<37 weeks)
  Yes 130 (74.7) 50 (37.6) 183 (59.0) 77 (13.2) <0.001
  No 43 (24.7) 83 (62.4) 126 (40.6) 503 (86.4)
  Not stated 1 (0.6) 0 (0.0) 1 (0.3) 2 (0.3)
Birth weight†, g, mean 2468.3 (±709.1) 2870.0 (±847.8) 2640.3 (±795.8) 3281.4 (±615.8) <0.001
Low birth weight †(<2500 g)
  Yes 81 (48.5) 38 (29.5) 120 (40.1) 54 (9.4) <0.001
  No 85 (50.9) 88 (68.2) 175 (58.5) 517 (89.6)
  Not stated 1 (0.6) 3 (2.3) 4 (1.3) 6 (1.0)
Small for gestational age†
  Yes 8 (4.8) 14 (10.9) 22 (7.4) 55 (9.5) 0.29
  No 158 (94.6) 112 (86.8) 273 (91.3) 516 (89.4)
  Not stated 1 (0.6) 3 (2.3) 4 (1.3) 6 (1.0)
Admission to NICU†
  Yes 130 (77.8) 51 (39.5) 183 (61.2) 90 (15.6) <0.001
  No 36 (21.6) 76 (58.9) 113 (37.8) 479 (83.0)
  Not stated 1 (0.6) 2 (1.6) 3 (1.0) 8 (1.4)
Apgar score at 5 min†
  <7 59 (35.3) 7 (5.4) 66 (22.1) 9 (1.6) <0.001
  7–10 106 (63.5) 120 (93.0) 229 (76.6) 559 (96.9)
  Not stated 2 (1.2) 2 (1.6) 4 (1.3) 9 (1.6)
Resuscitation†
  Yes 99 (59.3) 29 (22.5) 130 (43.5) 49 (8.5) <0.001
  No 65 (38.9) 96 (74.4) 162 (54.2) 520 (90.1)
  Not stated 3 (1.8) 4 (3.1) 7 (2.3) 8 (1.4)
Separation status†
  Discharged home 119 (71.3) 111 (86.0) 232 (77.6) 542 (93.9) <0.001
  Transferred to another 
health facility/other
41 (24.6) 16 (12.4) 58 (19.4) 28 (4.9)
  Neonatal death 2 (1.2) 1 (0.8) 3 (1.0) 5 (0.9)
  Not stated 5 (3.0) 1 (0.8) 6 (2.0) 2 (0.3)
*Case versus control.
†Live births only.
NICU, neonatal intensive care unit; PA, placenta accreta.
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7.8, 95% CI 3.1 to 19.9), resuscitation required (AOR: 
4.5, 95% CI 2.7 to 7.4) (table 4). These analyses included 
singleton births only and were adjusted for maternal age, 
BMI, smoking, number of previous caesarean sections, 
placenta praevia diagnosed prior to delivery and assisted 
reproductive technologies.
DIsCussIOn
The incidence of placenta accreta identified in this study 
was 44.2/100 000 women giving birth. This is similar to 
the rates reported previously from single-centre studies 
in individual hospitals in New Zealand (60.2/100000)15 
and Australia (38.8/100 000).16 This paper is the first to 
report on the national incidence of placenta accreta in 
both Australia and New Zealand.
The rates of placenta accreta reported previously 
vary markedly, both across geographic populations and 
as a result of different definitions of ‘placenta accreta’. 
The highest incidence has been reported in Israel at 
900/100 00017 and a lower rate of 40/100 000 has been 
reported in the USA.18 A review including 34 studies 
reported an average incidence of 189/100 000.4 More 
recently, the incidence of placenta accreta reported in 
the national United Kingdom Obstetric Surveillance 
System (UKOSS) was 17/100 000 women giving birth, 
from cases collected over a 12-month period in 2010–
2011.19 Both UKOSS and AMOSS are case–control studies 
that employed national active surveillance of cases. The 
UKOSS methods defined placenta accreta as ‘diagnosed 
histologically following hysterectomy or post-mortem 
or an abnormally adherent placenta, requiring active 
management, including conservative approaches where 
the placenta is left in situ’, whereas the AMOSS study also 
included cases of diagnosis by antenatal imaging. It is 
possible that some cases included in this study were diag-
nosed at antenatal imaging and not found to have placenta 
accreta at the time of birth, which is not uncommon.3 20 
Of the 295 included cases, 107 (36%) were recorded as 
diagnosed by antenatal imaging only, with no recorded 
confirmation of placenta accrete at delivery. Reports on 
the accuracy of ultrasound to diagnose placenta accreta 
are variable; however, antenatal imaging is generally 
considered to have a sensitivity of 77%–100% and spec-
ificity of 70%–98%.20–26 Further, 91/107 (85%) of these 
cases underwent hysterectomy following delivery, which 
suggests a confirmed diagnosis of placenta accreta, given 
that only 2/570; 0.4% of controls underwent hyster-
ectomy. This provides some reassurance that included 
cases had clinical placenta accreta, although it remains a 
possibility that the cases may have included some women 
who did not have confirmed placenta accreta, and there-
fore this study may have overestimated the incidence of 
placenta accreta. It is also possible that the higher inci-
dence of placenta accreta in Australasia as compared with 
the UK is a result of different exposure to risk factors. 
There appears to be a higher proportion of control 
women with risk factors for placenta accreta among the 
AMOSS cohort, for example, rates of prior caesarean 
section (18% vs 15%), pregnancy conceived from assisted 
reproductive technologies (2.6% vs 1%) and maternal 
age of 35 or older (27% vs 24%).
This study reports four independent risk factors for 
placenta accreta: older maternal age, prior caesarean 
section, placenta praevia diagnosed prior to birth and 
multiple birth; which have also been reported by other 
studies.4 27–29 Previous studies have also reported risk 
factors that this study did not find to be independent, 
specifically, smoking,30 use of assisted reproductive tech-
nologies31 and sex of fetus.32 Risk factors reported previ-
ously which were not measured in this study include 
hypertensive disorders, previous uterine surgery,17 33 
previous intrauterine procedures such as dilation and 
curettage34 35 and elevated second trimester serum levels 
of alpha-fetoprotein and free human chorionic 
gonadotrophin.32
Although the case definition establishes the outcome of 
this study as placenta accreta, it is important to consider 
the consequences of this condition for mother and 
baby. The maternal case fatality rate was 7/1000, with no 
maternal deaths among controls. The perinatal mortality 
rate was 39/1000 births for cases and 17/1000 births for 
controls. This is slightly higher than reported previously in 
this population and may be a result of the small numbers 
of deaths in this cohort (10/582) and the identification of 
controls as those delivering at the same hospital as cases, 
which are more likely to be tertiary hospitals.9
Maternal morbidity is high among women with 
placenta accreta. Just over one-third of cases (35%) were 
admitted to the ICU or HDU compared with less than 2% 
of controls. Two-thirds of cases underwent a hysterectomy 
(66.4%) compared with only 0.4% of controls. Hysterec-
tomy can be a devastating outcome for women wishing to 
expand their families and is itself a significant operation. 
In this study, 42% of cases had an unsuspected placenta 
accreta, and 43% of these had an unplanned hysterec-
tomy. Of cases undergoing a hysterectomy, 92.3% had at 
least one baby previously, compared with 69% having had 
a prior birth among cases who did not undergo a hyster-
ectomy. This likely reflects a higher incidence of placenta 
accreta in women with previous births and older maternal 
age and may also be due to a stronger motivation to retain 
the uterus in women undergoing their first birth.
Women with placenta accreta were more likely to give 
birth earlier, and consequently the babies born to these 
women were more often preterm, low birth weight, 
required resuscitation, admitted to NICU and were more 
likely to die. Women with a suspected placenta accreta 
had a 74.7% preterm birth rate, which may reflect the 
management of suspected accreta with planned caesarean 
section; however, the preterm birth rate was also much 
higher among those with an unsuspected placenta 
accreta compared with controls (37.6% vs 13.2%). Other 
studies have also reported higher preterm delivery rates 
and poorer outcomes for babies born to mothers with 
placenta accreta.36 However, this study did not find a 
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higher rate of small for gestational age babies among 
women with placenta accreta, which has been inconsis-
tently reported in other studies.4 37
Just over half of the cases included in this study had 
a placenta accreta suspected prior to delivery (169/295; 
57.3%). This is similar to the rate of suspected placenta 
accreta reported in the UKOSS study of 50%.19 It appears 
that women and babies with a suspected placenta accreta 
had inferior outcomes than those with an unknown 
placenta accreta, for example, higher rates of premature 
birth, hysterectomy and admission to ICU/HDU. This 
possibly reflects the higher index of suspicion around 
more severe cases, for example, one-third of suspected 
cases were diagnosed with a more severe form of placenta 
accreta (increta or percreta) compared with 19.5% of 
unsuspected cases.
The major strength of the AMOSS study design is the 
active surveillance for cases. Cases were captured as they 
occurred which minimised the risk of recall bias compared 
with traditional case–control studies. Although the case 
ascertainment is believed to be high, it is not possible to 
be sure of the exact level of ascertainment achieved. The 
study audited clinical records and did not solely depend 
on administrative datasets which are often unreliable, 
particularly for uncommon conditions.
A possible limitation of this study relates to the possible 
inclusion of cases which were diagnosed antenatally, but 
which were not confirmed clinically at operation or on 
pathology; however, this reflects diagnosis in real prac-
tice. Further, as it was not possible to assess how many of 
these cases were included, it was not possible to estimate 
the probability of misdiagnosis and consequent avoidable 
morbidity from unnecessary caesarean section. The inclu-
sion criteria was women giving birth, defined as at least 
400 g birth weight and/or at least 20 weeks’ gestation. 
Therefore, any cases of accreta that resulted in an early 
second trimester miscarriage were not included; however, 
the number of these cases is expected to be few. Addition-
ally, denominator data for the number of births in Austra-
lian hospitals is an estimate because of the varying start 
time for hospitals in the study. A further limitation is that 
information was not collected on all possible risk factors, 
and therefore we were not able to assess these.
Future research could explore the role of antenatal diag-
nosis and screening of women with risk factors for placenta 
accreta. A significant proportion of the cases in this study 
had an unsuspected placenta accreta, and nearly half of 
these underwent an unplanned hysterectomy. This is despite 
routine ultrasound for assessment of the placenta at approx-
imately 20 weeks’ gestation in these countries.
This national study from Australia and New Zealand 
confirms the incidence of placenta accreta in this 
high-income setting at approximately 1 in 2000 women 
giving birth. Although the condition remains rare, it is 
associated with a high risk of severe morbidity, and in 
a minority of cases, maternal death. The independent 
risk factors for placenta accreta in primiparous women 
were advanced maternal age and current multiple 
pregnancy. In multiparous women, previous caesarean 
birth and current placenta praevia were associated with 
an increased risk of placenta accreta. Further research on 
the role of antenatal diagnosis and screening in women 
with risk factors, particularly previous caesarean delivery, 
is warranted to inform clinical decision-making about 
place and mode of birth and to minimise risk of maternal 
and perinatal morbidity and mortality.
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